A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Psoriasis

In brief

Psoriasis is a chronic disease characterized by marked inflammation and thickening of the skin that results in thick, scaly skin plaques. This study assessed how safe and effective cedirogant (ABBV-157) was compared to placebo in adult participants with moderate to severe psoriasis. Efficacy and safety-related measurements assessed disease activity in participants with plaque psoriasis. Cedirogant (ABBV-157) is an investigational drug being developed for the treatment of chronic plaque psoriasis. Participants were put into 1 of 4 groups, called treatment arms and each group received a different treatment. There was a 1 in 4 chance that participants were assigned to placebo. Participants received oral daily doses of cedirogant or placebo capsules for 16 weeks. There may have been a higher burden for participants in this study compared to usual standard of care. Participants attended regular visits per routine clinical practice. The effect of the treatment was checked by medical assessments, checking for side effects, and questionnaires.

Key facts

Study ID

NCT05044234

Run by

AbbVie

People needed

156

Starts

2021-11-16

Expected to finish

2022-11-30

Last updated by the study team

2023-11-29

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants with stable moderate to severe plaque psoriasis of at least 6 months duration and who are candidates for systemic therapy or phototherapy.

You may not qualify if…

• Primary non-responders to previous anti-interleukin (IL)-17 (e.g., secukinumab, ixekizumab, brodalumab), anti-IL-23 (e.g., guselkumab, tildrakizumab, risankizumab), or anti-IL-12/23 (e.g., ustekinumab) treatment for chronic plaque psoriasis.
• Diagnosis of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication exacerbated psoriasis, or new onset guttate psoriasis or any other skin disease which may interfere with assessment of chronic plaque psoriasis.

Where it is running

• Medical Dermatology Specialist /ID# 238518 — Phoenix, Arizona, United States
• Arkansas Research Trials, LLC /ID# 238687 — North Little Rock, Arkansas, United States
• Encino Research Center /ID# 245950 — Encino, California, United States
• Velocity Clinical Research, Inc. /ID# 239536 — North Hollywood, California, United States
• Medderm Associates /ID# 238834 — San Diego, California, United States
• Lakes Research, LLC /ID# 238831 — Miami, Florida, United States
• Florida International Rsrch cr /ID# 245959 — Miami, Florida, United States
• Lenus Research & Medical Group /ID# 238695 — Sweetwater, Florida, United States
• Advanced Clinical Research Institute /ID# 238697 — Tampa, Florida, United States
• Clinical Research Trials of Florida, Inc. /ID# 238709 — Tampa, Florida, United States
• ForCare Clinical Research /ID# 238856 — Tampa, Florida, United States
• Cleaver Medical Group Dermatology - Dawsonville /ID# 246327 — Dawsonville, Georgia, United States
• Marietta Dermatology Clinical Research /ID# 238679 — Marietta, Georgia, United States
• Arlington Dermatology /ID# 238701 — Rolling Meadows, Illinois, United States
• Dawes Fretzin, LLC /ID# 238704 — Indianapolis, Indiana, United States
• Zel Skin & Laser Specialists - Edina /ID# 238714 — Edina, Minnesota, United States
• Skin Specialists, PC /ID# 238514 — Omaha, Nebraska, United States
• Forest Hills Dermatology Group /ID# 238708 — Kew Gardens, New York, United States
• Buffalo Medical Group /ID# 239068 — Williamsville, New York, United States
• Darst Dermatology /ID# 238677 — Charlotte, North Carolina, United States
• Wilmington Dermatology Center /ID# 246445 — Wilmington, North Carolina, United States
• Univ Hosp Cleveland /ID# 245953 — Cleveland, Ohio, United States
• Dermatologists of Southwest Ohio, Inc /ID# 238939 — Mason, Ohio, United States
• Oregon Dermatology and Research Center /ID# 238823 — Portland, Oregon, United States
• UAB Department of Dermatology /ID# 238563 — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.